Install
Research shows gut microbiome could delay onset of type 1 diabetes Race opens first Australian clinical site for RC220 Phase 1 solid tumour trial Biome secures news debt facility to support growth Algorae announces the appointment of chief commercial officer Percheron updates shareholders after disappointing clinical t
- 30articles · 30d
- 11+ hour agolatest article
- Aug 17, 2026earliest in window
- 97%with images
- 336avg words
- Medical 23
- Health & Wellness 20
- Health 13
- Economy, Business & Finance 11
- Business & Industrial 6
- Science & Technology 5
- Finance & Business 4
- News 4
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Australia secures sovereign viral vector manufacturing as VVMF wins TGA licence
5+ day, 8+ hour ago (368+ words) BiotechDispatch Australia secures sovereign viral vector manufacturing as VVMF wins TGA licence A Sydney company has become the first in Australia to earn a manufacturing licence for viral vectors, a milestone it says strengthens the nation's capacity to make advanced…...
US health agency funds broad access trial for Melbourne biotech's ALS drug
5+ day, 9+ hour ago (444+ words) The United States National Institutes of Health has agreed to fund a multimillion-dollar program that will give up to 200 Americans living with motor neurone disease access to an experimental treatment developed by the Melbourne-based biotechnology company Neurizon Therapeutics. The grant,…...
Arovella Therapeutics moves 'off-the-shelf' cell therapy from lab to patients
1+ week, 14+ hour ago (412+ words) BiotechDispatch Arovella Therapeutics moves 'off-the-shelf' cell therapy from lab to patients Arovella Therapeutics has taken a step toward treating blood cancer patients with donor-derived cells rather than their own, announcing that it has released its first clinical manufacturing batch of…...
Alterity secures option underwriting as it prepares for pivotal MSA trial
2+ week, 13+ hour ago (279+ words) Alterity Therapeutics has secured an underwriting agreement that could provide at least $4.2 million in additional funding as the company prepares to begin its planned Phase 3 clinical trial of ATH434 in multiple system atrophy. The Melbourne- and San Francisco-based biotechnology company said…...
Genetic Signatures reshapes for growth after reducing losses and securing Danish hospital deal
2+ week, 6+ day ago (624+ words) Genetic Signatures has emerged from a year of restructuring with smaller losses, lower cash burn, and a clearer plan to rebuild growth, despite a decline in revenue amid challenging conditions in its core Australian market. The molecular diagnostics company reported…...
Neuren secures European approval for Rett syndrome treatment
2+ week, 6+ day ago (354+ words) Neuren Pharmaceuticals has reached a major milestone in the global commercialisation of trofinetide after the European Commission granted marketing authorisation for DAYBU to treat neurobehavioural symptoms associated with Rett syndrome. The approval makes DAYBU the first and only authorised treatment…...
Dimerix takes control of US development pathway for new kidney injury treatment
3+ week, 6+ day ago (311+ words) Dimerix has taken over sponsorship of a United States investigational new drug application for DMX-652, giving the Australian biotechnology company direct control of clinical development plans for its newly acquired acute kidney injury asset. The Melbourne-based company said the transfer from…...